$2.20
0.052.33%
Last update: May 20, 10:37 AM
Grace Therapeutics Inc Analyst Ratings
GRCENASDAQ
Grace Therapeutics Analyst Ratings and Price Targets | NASDAQ:GRCE | Benzinga
Grace Therapeutics Inc has a consensus price target of $10 based on the ratings of 2 analysts. The high is $12 issued by HC Wainwright & Co. on February 18, 2025. The low is $8 issued by TD Cowen on April 24, 2026. The 2 most-recent analyst ratings were released by TD Cowen and HC Wainwright & Co. on April 24, 2026 and February 18, 2025, respectively. With an average price target of $10 between TD Cowen and HC Wainwright & Co., there's an implied 354.55% upside for Grace Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Grace Therapeutics
Loading calendar...
FAQ
What is the target price for Grace Therapeutics (GRCE) stock?
The latest price target for Grace Therapeutics (NASDAQ:GRCE) was reported by TD Cowen on April 24, 2026. The analyst firm set a price target for $8.00 expecting GRCE to rise to within 12 months (a possible 263.64% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Grace Therapeutics (GRCE)?
The latest analyst rating for Grace Therapeutics (NASDAQ:GRCE) was provided by TD Cowen, and Grace Therapeutics maintained their buy rating.
When was the last upgrade for Grace Therapeutics (GRCE)?
There is no last upgrade for Grace Therapeutics
When was the last downgrade for Grace Therapeutics (GRCE)?
There is no last downgrade for Grace Therapeutics.
When is the next analyst rating going to be posted or updated for Grace Therapeutics (GRCE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Grace Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Grace Therapeutics was filed on April 24, 2026 so you should expect the next rating to be made available sometime around April 24, 2027.
Is the Analyst Rating Grace Therapeutics (GRCE) correct?
While ratings are subjective and will change, the latest Grace Therapeutics (GRCE) rating was a maintained with a price target of $12.00 to $8.00. The current price Grace Therapeutics (GRCE) is trading at is $2.20, which is out of the analyst’s predicted range.
